Cns Drugs, 1172-7047

Journal

  1. 2017
  2. Ardura-Fabregat, A., Boddeke, E. W. G. M., Boza-Serrano, A., Brioschi, S., Castro-Gomez, S., Ceyzeriat, K., ... Yang, Y. (2017). Targeting Neuroinflammation to Treat Alzheimer's Disease. Cns Drugs, 31(12), 1057-1082. https://doi.org/10.1007/s40263-017-0483-3
  3. 2016
  4. Alvarez-Jimenez, M., O'Donoghue, B., Thompson, A., Gleeson, J. F., Bendall, S., Gonzalez-Blanch, C., ... McGorry, P. D. (2016). Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era. Cns Drugs, 30(5), 357-368. https://doi.org/10.1007/s40263-016-0331-x
  5. 2015
  6. 2010
  7. Smink, B. E., Egberts, A. C. G., Lusthof, K. J., Uges, D. R. A., & de Gier, J. I. (2010). The Relationship between Benzodiazepine Use and Traffic Accidents A Systematic Literature Review. Cns Drugs, 24(8), 639-653.
  8. 2008
  9. 2007
  10. 2004
  11. Bosker, F. J., Westerink, B. H. C., Cremers, T. I. F. H., Gerrits, M., van der Hart, M. G. C., Kuipers, S. D., ... Korf, J. (2004). Future antidepressants - What is in the pipeline and what is missing? Cns Drugs, 18(11), 705 - 732.
  12. 2003
  13. 2000

ID: 1245993